Back to Search
Start Over
Relaxin reduces endothelium-derived vasoconstriction in hypertension: Revealing new therapeutic insights.
- Source :
- British Journal of Pharmacology; Jan2020, Vol. 177 Issue 1, p217-233, 17p, 10 Graphs
- Publication Year :
- 2020
-
Abstract
- <bold>Background and Purpose: </bold>Endothelium-derived vasoconstriction is a hallmark of vascular dysfunction in hypertension. In some cases, an overproduction of endothelium-derived prostacyclin (PGI2 ) can cause contraction rather than relaxation. Relaxin is well known for its vasoprotective actions, but the possibility that this peptide could also reverse endothelium-derived vasoconstriction has never been investigated. We tested the hypothesis that short-term relaxin treatment mitigates endothelium-derived vasoconstriction in spontaneously hypertensive rats (SHR).<bold>Experimental Approach: </bold>Male Wistar Kyoto rats (WKY) and SHR were subcutaneously infused with either vehicle (20 mmol·L-1 sodium acetate) or relaxin (13.3 μg·kg-1 ·hr-1 ) using osmotic minipumps for 3 days. Vascular reactivity to the endothelium-dependent agonist ACh was assessed in vitro by wire myography. Quantitative PCR and LC-MS were used to identify changes in gene expression of prostanoid pathways and PG production, respectively.<bold>Key Results: </bold>Relaxin treatment ameliorated hypertension-induced endothelial dysfunction by increasing NO-dependent relaxation and reducing endothelium-dependent contraction. Notably, short-term relaxin treatment up-regulated mesenteric PGI2 receptor (IP) expression, permitting PGI2 -IP-mediated vasorelaxation. In the aorta, reversal of contraction was accompanied by suppression of the hypertension-induced increase in prostanoid-producing enzymes and reduction in PGI2 -evoked contractions.<bold>Conclusions and Implications: </bold>Relaxin has region-dependent vasoprotective actions in hypertension. Specifically, relaxin has distinct effects on endothelium-derived contracting factors and their associated vasoconstrictor pathways in mesenteric arteries and the aorta. Taken together, these observations reveal the potential of relaxin as a new therapeutic agent for vascular disorders that are associated with endothelium-derived vasoconstriction including hypertension. [ABSTRACT FROM AUTHOR]
- Subjects :
- MESENTERIC artery
ENDOTHELIUM
ENDOTHELINS
VASOCONSTRICTION
RELAXIN
SODIUM acetate
HYPERTENSION
ANGIOTENSIN I
THERAPEUTIC use of sex hormones
RESEARCH
ANIMAL experimentation
RESEARCH methodology
MEDICAL cooperation
EVALUATION research
RATS
COMPARATIVE studies
SEX hormones
DOSE-effect relationship in pharmacology
RESEARCH funding
Subjects
Details
- Language :
- English
- ISSN :
- 00071188
- Volume :
- 177
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- British Journal of Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 141335783
- Full Text :
- https://doi.org/10.1111/bph.14858